Publication:
Antituberculosis drug resistance patterns in adults with tuberculous meningitis: Results of Haydarpasa-iv study

dc.contributor.buuauthorYılmaz, Emel
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentEnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı
dc.contributor.researcheridHJZ-6992-2023
dc.contributor.scopusid22037135100
dc.date.accessioned2024-03-13T12:05:55Z
dc.date.available2024-03-13T12:05:55Z
dc.date.issued2015-11-04
dc.description.abstractBackground: Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs is an increasingly common clinical problem. This study aimed to evaluate drug resistance profiles of TBM isolates in adult patients in nine European countries involving 32 centers to provide insight into the empiric treatment of TBM. Methods: Mycobacterium tuberculosis was cultured from the cerebrospinal fluid (CSF) of 142 patients and was tested for susceptibility to first-line antituberculosis drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol (EMB). Results: Twenty of 142 isolates (14.1 %) were resistant to at least one antituberculosis drug, and five (3.5 %) were resistant to at least INH and RIF, [multidrug resistant (MDR)]. The resistance rate was 12, 4.9, 4.2 and 3.5 % for INH, SM, EMB and RIF, respectively. The monoresistance rate was 6.3, 1.4 and 0.7 % for INH, SM and EMB respectively. There was no monoresistance to RIF. The mortality rate was 23.8 % in fully susceptible cases while it was 33.3 % for those exhibiting monoresistance to INH, and 40 % in cases with MDR-TBM. In compared to patients without resistance to any firstline drug, the relative risk of death for INH-monoresistance and MDR-TBM was 1.60 (95 % CI, 0.38-6.82) and 2.14 (95 % CI, 0: 34-13: 42), respectively. Conclusion: INH-resistance and MDR rates seemed not to be worrisome in our study. However, considering their adverse effects on treatment, rapid detection of resistance to at least INH and RIF would be most beneficial for designing anti-TB therapy. Still, empiric TBM treatment should be started immediately without waiting the drug susceptibility testing.
dc.identifier.citationYılmaz, E. vd. (2015). "Antituberculosis drug resistance patterns in adults with tuberculous meningitis: Results of Haydarpasa-iv study". Annals of Clinical Microbiology and Antimicrobials, 14(1).
dc.identifier.issn1476-0711
dc.identifier.issue1
dc.identifier.pubmed26538030
dc.identifier.scopus2-s2.0-84946225326
dc.identifier.urihttps://doi.org/10.1186/s12941-015-0107-z
dc.identifier.urihttps://hdl.handle.net/11452/40379
dc.identifier.volume14
dc.identifier.wos000364000400001
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherBMC
dc.relation.collaborationYurt içi
dc.relation.collaborationYurt dışı
dc.relation.collaborationSanayi
dc.relation.journalAnnals of Clinical Microbiology and Antimicrobials
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMicrobiology
dc.subjectTuberculosis
dc.subjectMeningitis
dc.subjectResistance
dc.subjectMDR
dc.subjectIsoniazid
dc.subjectDiagnosis
dc.subjectAfrica
dc.subjectDeath
dc.subject.emtreeEthambutol
dc.subject.emtreeIsoniazid
dc.subject.emtreeRifampicin
dc.subject.emtreeStreptomycin
dc.subject.emtreeTuberculostatic agent
dc.subject.emtreeAdult
dc.subject.emtreeArticle
dc.subject.emtreeBacterial strain
dc.subject.emtreeBacterium culture
dc.subject.emtreeBacterium isolate
dc.subject.emtreeCerebrospinal fluid
dc.subject.emtreeControlled study
dc.subject.emtreeDrug sensitivity
dc.subject.emtreeFemale
dc.subject.emtreeHuman
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMortality
dc.subject.emtreeMulticenter study
dc.subject.emtreeMultidrug resistant tuberculosis
dc.subject.emtreeMycobacterium tuberculosis
dc.subject.emtreeRetrospective study
dc.subject.emtreeRisk factor
dc.subject.emtreeTuberculous meningitis
dc.subject.emtreeAdolescent
dc.subject.emtreeAged
dc.subject.emtreeAntibiotic resistance
dc.subject.emtreeClinical trial
dc.subject.emtreeDrug effects
dc.subject.emtreeEurope
dc.subject.emtreeIsolation and purification
dc.subject.emtreeMicrobiology
dc.subject.emtreeMiddle aged
dc.subject.emtreePrevalence
dc.subject.emtreeSurvival analysis
dc.subject.emtreeTuberculosis, meningeal
dc.subject.emtreeVery elderly
dc.subject.emtreeYoung adult
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntitubercular agents
dc.subject.meshCerebrospinal fluid
dc.subject.meshDrug resistance, bacterial
dc.subject.meshEurope
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshMycobacterium tuberculosis
dc.subject.meshPrevalence
dc.subject.meshRetrospective studies
dc.subject.meshSurvival analysis
dc.subject.meshTuberculosis, meningeal
dc.subject.meshYoung adult
dc.subject.scopusMeningeal tuberculosis; Tuberculoma; Central nervous system tuberculosis
dc.subject.wosMicrobiology
dc.titleAntituberculosis drug resistance patterns in adults with tuberculous meningitis: Results of Haydarpasa-iv study
dc.typeArticle
dc.wos.quartileN/A
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Yilmaz_vd_2015.pdf
Size:
1002.85 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: